Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of lignans compound in preparation of anti-hepatic fibrosis medicine

A technology of lignans and compounds, which is applied in the application field of lignans in the preparation of anti-hepatic fibrosis drugs, can solve the problems that lignans do not form a system, lack batch or large-scale preparation methods, etc., and achieve Strong anti-hepatic stellate cell proliferation, good biological activity

Active Publication Date: 2018-01-19
BEIJING INSTITUTE OF TECHNOLOGYGY
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, the extraction and separation of lignans has not yet formed a systematic and standardized method, especially the lack of methods suitable for batch or large-scale preparation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lignans compound in preparation of anti-hepatic fibrosis medicine
  • Application of lignans compound in preparation of anti-hepatic fibrosis medicine
  • Application of lignans compound in preparation of anti-hepatic fibrosis medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] The preparation method of embodiment 1 compound

[0035] The lignan compounds described in this example are extracted from natural Bupleurum chinensis, and the specific process is as follows:

[0036] 1) Take 15 kg of dried bamboo-leaf Bupleurum chinensis (produced in Yunnan, China) and grind it into a coarse powder, heat and reflux extraction with 9 times the amount of 75% ethanol for 3 times, each time for 1 hour, filter, combine the filtrates, concentrate under reduced pressure to remove ethanol, Stir and add water to dilute to 40L, and sequentially extract with petroleum ether, ethyl acetate, n-butanol and water. The extracts were collected and rotovaped to obtain individual fractions.

[0037] 2) Dissolve the extracted part of ethyl acetate in ethyl acetate to make the concentration reach 20-50 mg / ml, pass through 200-300 mesh silica gel column chromatography, use petroleum ether-ethyl acetate system with 4:1 (v / v) , 1:1 (v / v), 1:8 (v / v), 1:20 (v / v), pure methano...

Embodiment 2

[0052] Example 2 In vitro inhibition of activated hepatic stellate cells by MTT method

[0053] In this example, the hepatic stellate cell experiment of in vitro inhibition by MTT method was carried out for the lignan compounds described in the present invention.

[0054] Experimental materials: human hepatic stellate cell line LX-2, rat hepatic stellate cell line T-6

[0055] Drugs to be tested: 15 compounds were prepared with final concentration gradients of 100 μM, 20 μM, 4 μM, 0.8 μM and 0.16 μM.

[0056] Positive control: Saikosaponin d was prepared with final concentration gradients of 100 μM, 20 μM, 4 μM, 0.8 μM and 0.16 μM.

[0057] Taking human hepatic stellate cell line LX-2 as an example, the inhibitory effect of 15 compounds on activated hepatic stellate cells was determined by MTT method.

[0058] (1) Count the LX-2 human hepatic stellate cell line, and make the cells 5×10 4 cells / mL of cell suspension.

[0059] (2) Take the cell suspension and inoculate it in...

Embodiment 3

[0069] Example 3 Anti-hepatic fibrosis experiment in rats

[0070] In this example, an in vivo anti-hepatic fibrosis experiment in rats was carried out for the compound described in the present invention.

[0071] Experimental animals: male SD rats, SPF grade, 6-8 weeks old, weighing 180+-20, purchased from the Experimental Animal Center of the Chinese Academy of Military Medical Sciences, certificate number: SCXK-(Army) 2012-2004. Normal adaptive feeding Conditions: Breeding in independent isolation cages, temperature 18-21°C, humidity >40%, 150Pa pressurized air supply, cycle light (12h light, 12h dark), free access to water and food (standard pellet feed), change the pad every other day feed and fodder.

[0072] Experimental grouping: 265 experimental rats were randomly divided into 18 groups, which were normal group (10 rats), model group (15 rats), compound 1a group (15 rats), compound 1b group (15 rats), compound 1c group ( 15 rats), compound 1d group (15 rats), compou...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of a lignans compound in preparation of an anti-hepatic fibrosis medicine. In-vitro, in-vivo and molecular-level tests prove that the lignans compound has strongeffect of inhibiting proliferation of hepatic stellate cells and resisting the hepatic fibrosis, and also has lower IC50 value to matrix metalloproteinase-2 (MMP2), matrix metalloproteinase-9 (MMP9) and transforming growth factor-beta1 (TGF-beta1). The lignans compound can be combined with the substances mentioned hereinabove and can inhibit the bioactivities of the substances, so that the lignanscompound can be used as an anti-hepatic fibrosis medicine.

Description

technical field [0001] The invention relates to the field of natural product chemical drugs, in particular to the application of a lignan compound in the preparation of anti-hepatic fibrosis drugs. Background technique [0002] Liver fibrosis is a pathological change caused by chronic liver damage caused by various reasons. It is characterized by excessive and abnormal deposition of extracellular matrix components in the liver, which affects the function of the liver. It is a necessary stage for the development of chronic liver disease to cirrhosis. Studies have shown that liver fibrosis may be reversed to normal, but if it progresses to liver cirrhosis, there is no possibility of reversal. Therefore, finding drugs for the treatment of liver fibrosis is a hot research topic of many scholars. Although some progress has been made in the diagnosis and treatment of liver fibrosis, there is still a lack of definitive and effective drugs. However, medicinal materials rich in lign...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61K31/7048A61P1/16C07D307/33C07D407/06C07D307/58C07D307/92C07H15/26C07H1/08
CPCA61K31/365A61P1/16C07D307/58C07D407/06
Inventor 戴荣继刘秀洁邓玉林孟薇薇
Owner BEIJING INSTITUTE OF TECHNOLOGYGY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com